Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers.


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
05 10 2020
Historique:
received: 29 04 2020
revised: 03 06 2020
accepted: 04 06 2020
entrez: 25 6 2020
pubmed: 25 6 2020
medline: 11 3 2021
Statut: ppublish

Résumé

Rare individuals can naturally clear chronic hepatitis B virus (HBV) infection and acquire protection from reinfection as conferred by vaccination. To examine the protective humoral response against HBV, we cloned and characterized human antibodies specific to the viral surface glycoproteins (HBsAg) from memory B cells of HBV vaccinees and controllers. We found that human HBV antibodies are encoded by a diverse set of immunoglobulin genes and recognize various conformational HBsAg epitopes. Strikingly, HBsAg-specific memory B cells from natural controllers mainly produced neutralizing antibodies able to cross-react with several viral genotypes. Furthermore, monotherapy with the potent broadly neutralizing antibody Bc1.187 suppressed viremia in vivo in HBV mouse models and led to post-therapy control of the infection in a fraction of animals. Thus, human neutralizing HBsAg antibodies appear to play a key role in the spontaneous control of HBV and represent promising immunotherapeutic tools for achieving HBV functional cure in chronically infected humans.

Identifiants

pubmed: 32579155
pii: 151888
doi: 10.1084/jem.20200840
pmc: PMC7537403
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Epitopes 0
Hepatitis B Surface Antigens 0
Hepatitis B Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 Hehle et al.

Déclaration de conflit d'intérêts

Disclosures: V. Hehle reported a patent to anti-HBV antibodies and methods of use, pending. M. Beretta reported a patent to anti-HBV antibodies and methods of use, pending. M. Bourgine reported a patent to anti-HBV antibodies and methods of use, pending. M. Ait-Goughoulte reported a patent planned on the antibodies pending, "Roche." S. Pol reported personal fees from Gilead, Abbvie, BMS, Janssen, and Roche outside the submitted work. H. Strick-Marchand reported a patent to human neutralizing HBV antibodies and their use thereof, pending. N. Pelletier reported personal fees from Hoffmann-La Roche outside the submitted work; in addition, N. Pelletier had a patent planned to be submitted, pending "Roche Innovation Center Basel." H. Mouquet reported grants from Institut Roche during the conduct of the study; in addition, H. Mouquet had a patent to anti-HBV antibodies and methods of use, pending. No other disclosures were reported.

Références

J Clin Invest. 2018 Oct 1;128(10):4573-4587
pubmed: 30084841
Gastroenterology. 2015 Jan;148(1):221-244.e3
pubmed: 25447852
Science. 2003 Sep 5;301(5638):1374-7
pubmed: 12920303
Eur J Immunol. 2016 Oct;46(10):2340-2351
pubmed: 27469325
Vaccine. 1996 Aug;14(11):1019-27
pubmed: 8879096
Clin Gastroenterol Hepatol. 2019 Oct 4;:
pubmed: 31589980
J Exp Med. 2004 Jan 5;199(1):145-50
pubmed: 14699083
PLoS One. 2015 Mar 17;10(3):e0119820
pubmed: 25782010
Proc Natl Acad Sci U S A. 1984 Dec;81(24):7708-12
pubmed: 6096851
PLoS One. 2015 Nov 04;10(11):e0142145
pubmed: 26536627
Nat Rev Gastroenterol Hepatol. 2009 Aug;6(8):453-62
pubmed: 19581904
Hepatology. 2002 Mar;35(3):673-9
pubmed: 11870383
Gut. 2012 Dec;61(12):1754-64
pubmed: 22157327
J Immunol. 2006 Nov 1;177(9):6517-26
pubmed: 17056584
J Immunol. 2016 Apr 1;196(7):3079-87
pubmed: 26936879
Liver. 2001 Jun;21(3):207-12
pubmed: 11422784
Lancet. 1990 Jun 23;335(8704):1529
pubmed: 1972457
J Gen Virol. 2009 Jan;90(Pt 1):127-35
pubmed: 19088281
Immunity. 2007 Feb;26(2):205-13
pubmed: 17306569
J Immunol Methods. 2015 Jul;422:102-10
pubmed: 25910833
Virus Res. 2016 Jan 4;211:209-21
pubmed: 26541316
J Hepatol. 2016 Apr;64(1 Suppl):S102-S116
pubmed: 27084031
Nat Rev Drug Discov. 2019 Nov;18(11):827-844
pubmed: 31455905
Dig Dis. 2011;29(4):423-33
pubmed: 21894014
Hepatology. 2000 Sep;32(3):588-96
pubmed: 10960454
Gastroenterology. 2017 Dec;153(6):1647-1661.e9
pubmed: 28851562
J Viral Hepat. 2017 Jun;24(6):506-513
pubmed: 28012213
J Hepatol. 2012 Oct;57(4):720-9
pubmed: 22634131
Nucleic Acids Res. 2013 Jan;41(Database issue):D566-70
pubmed: 23125365
Mol Immunol. 1999 Jul;36(10):669-83
pubmed: 10509818
J Virol. 2013 May;87(10):5554-63
pubmed: 23468504
Hum Vaccin Immunother. 2017 Aug 3;13(8):1768-1773
pubmed: 28521640
J Hepatol. 2016 Apr;64(1 Suppl):S71-S83
pubmed: 27084039
Curr Opin Virol. 2018 Jun;30:48-57
pubmed: 29738926
Blood. 2019 Jan 10;133(2):137-146
pubmed: 30341058
Cell Mol Immunol. 2015 May;12(3):309-16
pubmed: 25849120
Cell Rep. 2019 Apr 9;27(2):572-585.e7
pubmed: 30970259
J Clin Invest. 2018 Oct 1;128(10):4588-4603
pubmed: 30091725
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Nature. 1982 Aug 5;298(5874):567-9
pubmed: 7099252
Elife. 2017 Sep 26;6:
pubmed: 28949917
Methods Mol Biol. 2010;640:463-73
pubmed: 20645068
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):E3268-77
pubmed: 23115339
Gastroenterology. 2019 Jan;156(2):325-337
pubmed: 30367834
N Engl J Med. 1993 Dec 16;329(25):1842-7
pubmed: 8247035
Curr Opin Virol. 2018 Jun;30:68-79
pubmed: 29775812
Sci Transl Med. 2015 Dec 2;7(316):316ra192
pubmed: 26631631
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):662-675
pubmed: 31548710
Gut. 2016 Apr;65(4):658-71
pubmed: 26423112
Cell Rep. 2018 May 29;23(9):2568-2581
pubmed: 29847789
J Virol. 2009 Sep;83(18):9321-8
pubmed: 19570861
Hepatology. 2009 May;49(5 Suppl):S45-55
pubmed: 19399792
Hepatology. 2016 Jan;63(1):35-48
pubmed: 26224662
Proc Natl Acad Sci U S A. 1982 Jan;79(2):650-4
pubmed: 6952217
Trends Microbiol. 2015 Oct;23(10):653-665
pubmed: 26433697
Sci Signal. 2012 Jan 03;5(205):ra1
pubmed: 22215732
Curr Opin Virol. 2019 Feb;34:149-159
pubmed: 30884330

Auteurs

Verena Hehle (V)

Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1222, Paris, France.

Maxime Beretta (M)

Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1222, Paris, France.

Maryline Bourgine (M)

Molecular Virology and Vaccinology Unit, Institut Pasteur, Paris, France.

Malika Ait-Goughoulte (M)

Roche Innovation Center, Basel, Switzerland.

Cyril Planchais (C)

Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1222, Paris, France.

Solen Morisse (S)

Molecular Virology and Vaccinology Unit, Institut Pasteur, Paris, France.

Benjamin Vesin (B)

Molecular Virology and Vaccinology Unit, Institut Pasteur, Paris, France.

Valérie Lorin (V)

Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1222, Paris, France.

Thierry Hieu (T)

Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1222, Paris, France.

Andrea Stauffer (A)

Roche Innovation Center, Basel, Switzerland.

Oriane Fiquet (O)

Innate Immunity Unit, Department of Immunology, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1223, Institut Pasteur, Paris, France.

Jordan D Dimitrov (JD)

Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris, Paris, France.

Marie-Louise Michel (ML)

Institut Pasteur, Paris, France.

Marie-Noëlle Ungeheuer (MN)

Investigation Clinique et Accès aux Ressources Biologiques platform, Center for Translational Science, Institut Pasteur, Paris, France.

Camille Sureau (C)

Institut National de la Transfusion Sanguine, Centre National de la Recherche-Institut National de la Santé et de la Recherche Médicale U1134, Paris, France.

Stanislas Pol (S)

Institut National de la Santé et de la Recherche Médicale U1223, Institut Pasteur, Paris, France.
Hepatology Department, Cochin Hospital, Assistance publique - Hôpitaux de Paris, Paris, France.

James P Di Santo (JP)

Innate Immunity Unit, Department of Immunology, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1223, Institut Pasteur, Paris, France.

Hélène Strick-Marchand (H)

Innate Immunity Unit, Department of Immunology, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1223, Institut Pasteur, Paris, France.

Nadège Pelletier (N)

Roche Innovation Center, Basel, Switzerland.

Hugo Mouquet (H)

Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1222, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH